HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.

Abstract
Cilengitide, a cyclicized arginine-glycine-aspartic acid-containing pentapeptide, potently blocks ανβ3 and ανβ5 integrin activation. Integrins are upregulated in many malignancies and mediate a wide variety of tumor-stroma interactions. Cilengitide and other integrin-targeting therapeutics have preclinical activity against many cancer subtypes including glioblastoma (GBM), the most common and deadliest CNS tumor. Cilengitide is active against orthotopic GBM xenografts and can augment radiotherapy and chemotherapy in these models. In Phase I and II GBM trials, cilengitide and the combination of cilengitide with standard temozolomide and radiation demonstrate consistent antitumor activity and a favorable safety profile. Cilengitide is currently under evaluation in a pivotal, randomized Phase III study (Cilengitide in Combination With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Phase III Randomized Clinical Trial [CENTRIC]) for newly diagnosed GBM. In addition, randomized controlled Phase II studies with cilengitide are ongoing for non-small-cell lung cancer and squamous cell carcinoma of the head and neck. Cilengitide is the first integrin inhibitor in clinical Phase III development for oncology.
AuthorsDavid A Reardon, Bart Neyns, Michael Weller, Joerg Christian Tonn, Louis Burt Nabors, Roger Stupp
JournalFuture oncology (London, England) (Future Oncol) Vol. 7 Issue 3 Pg. 339-54 (Mar 2011) ISSN: 1744-8301 [Electronic] England
PMID21417900 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Integrins
  • Oligopeptides
  • Snake Venoms
  • Cilengitide
  • arginyl-glycyl-aspartic acid
Topics
  • Animals
  • Antineoplastic Agents (adverse effects, chemistry, pharmacokinetics, therapeutic use)
  • Clinical Trials as Topic
  • Drug Evaluation, Preclinical
  • Drug Industry (trends)
  • Glioblastoma (drug therapy)
  • Humans
  • Integrins (antagonists & inhibitors)
  • Oligopeptides (adverse effects, chemistry, pharmacokinetics, therapeutic use)
  • Snake Venoms (adverse effects, chemistry, pharmacokinetics, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: